

# Table of Contents

Preface to the First Edition . . . . .	xxvii
Preface to the Second Edition . . . . .	xxxi
<b>1. Overview of Hematopoietic Stem Cell Transplantation . . . . .</b>	<b>1</b>
<i>John R. Wingard, MD</i>	
I. Historical Perspective . . . . .	1
II. A Primer of the Transplant Procedure . . . . .	4
III. General Aspects About Different Types of HSCT . . . . .	5
IV. What This Book Is About . . . . .	8
<b>2. Common Uses of Hematopoietic Stem Cell Transplantation. . . . .</b>	<b>9</b>
<i>Joseph H. Antin, MD, and John R. Wingard, MD</i>	
I. Introduction . . . . .	9
II. Marrow Failure . . . . .	9
III. Hematologic Malignancies . . . . .	14
IV. References/Suggested Readings. . . . .	26
<b>3. Hematopoietic Stem Cell Transplantation for Nonmalignant Disorders . . . . .</b>	<b>29</b>
<i>Shalini Shenoy, MD</i>	
I. Introduction . . . . .	29
II. Marrow Failure Syndromes . . . . .	30
III. Metabolic Disorders . . . . .	32
IV. Immune Deficiency/Dysfunction Disorders . . . . .	34
V. Hemoglobinopathies . . . . .	37
VI. Miscellaneous Rare Genetic Disorders . . . . .	39
VII. Summary . . . . .	40
VIII. References/Suggested Readings. . . . .	40
<b>4. Patient Evaluation Before Transplantation (Adult) . . . . .</b>	<b>43</b>
<i>Jack W. Hsu, MD; Mehdi Hamadani, MD; and Steven M. Devine, MD</i>	
I. Introduction . . . . .	43
II. Initial Consultation . . . . .	44
III. Assessment of Disease Status . . . . .	47
IV. Assessment of Physiologic Status . . . . .	49
V. Psychological, Financial, and Caregiver Considerations . . . . .	57
VI. References/Suggested Readings . . . . .	57

<b>5. Patient Evaluation Before Transplantation (Pediatric)</b> . . . . .	<b>59</b>
<i>Nancy A. Kernan, MD</i>	
I. Overview . . . . .	59
II. Assessment at Time of Referral . . . . .	60
III. Assessment of Disease Status . . . . .	60
IV. Assessment of Physiologic Function . . . . .	61
<b>6. Venous Access for Hematopoietic Stem Cell Transplantation</b>	
<b>Patients</b> . . . . .	<b>65</b>
<i>James C. Andrews, MD, FSIR</i>	
I. General Principles . . . . .	65
II. Options for Chronic Central Venous Access . . . . .	72
III. Managing Central Venous Access Problems . . . . .	74
IV. Summary . . . . .	80
V. References/Suggested Readings . . . . .	81
<b>7. Conditioning Regimens</b> . . . . .	<b>83</b>
<i>Javier Bolaños-Meade, MD, and Richard J. Jones, MD</i>	
I. Introduction . . . . .	83
II. Common Myeloablative Regimens . . . . .	84
III. Common Nonmyeloablative/RIC . . . . .	86
IV. Toxicities . . . . .	86
V. Antiemetic Management . . . . .	88
VI. Selecting the Optimal Regimen . . . . .	88
VII. References/Suggested Readings . . . . .	91
<b>8. Hematopoietic Progenitor Cell Donor Evaluation</b> . . . . .	<b>93</b>
<i>John P. Miller, MD, PhD</i>	
I. Introduction . . . . .	93
II. Types of Hematopoietic Progenitor Cell Donation . . . . .	93
III. Medical Evaluation of HPC Donors . . . . .	94
IV. Donor Consent for HPC Donation . . . . .	102
V. Subsequent Donations . . . . .	105
VI. Summary . . . . .	106
VII. References/Suggested Readings . . . . .	106
<b>9. Optimal Donor Selection for Allogeneic Hematopoietic</b>	
<b>Stem Cell Transplantation.</b> . . . . .	<b>109</b>
<i>Aleksandr Lazaryan, MD, MPH, PhD, and Daniel J. Weisdorf, MD</i>	
I. Introduction . . . . .	109
II. Related Donors . . . . .	110
III. Adult Volunteer Unrelated Donors . . . . .	113
IV. Umbilical Cord Blood . . . . .	118

V.	Summary .....	126
VI.	References/Suggested Readings .....	126
<b>10.</b>	<b>HLA .....</b>	<b>129</b>
	<i>Effie W. Petersdorf, MD</i>	
I.	The Major Histocompatibility Complex.....	129
II.	HLA Typing in Support of Allogeneic Transplant Programs .....	135
III.	The Transplant Barrier.....	140
IV.	References/Suggested Readings .....	143
<b>11.</b>	<b>HLA-Haploidentical Hematopoietic Stem Cell Transplantation .....</b>	<b>145</b>
	<i>Christopher G. Kanakry, MD, and Ephraim J. Fuchs, MD, MBA</i>	
I.	HLA Transplantation .....	145
II.	Modern Approaches to HLA-Haploidentical Transplantation .....	147
III.	T-Cell-Replete HLA-Haploidentical HSCT .....	154
IV.	Reasons for Failure of HLA-Haploidentical HSCT .....	163
V.	Conclusion .....	164
VI.	References/Suggested Readings .....	164
<b>12.</b>	<b>Pediatric Aspects of Hematopoietic Stem Cell Transplantation...</b>	<b>167</b>
	<i>Kimberly A. Kasow, DO, and Gregory A. Hale, MD</i>	
I.	Overview .....	167
II.	Malignant Indications for Allogeneic Transplantation .....	167
III.	Nonmalignant Indications for Transplantation .....	169
IV.	Indications for Autologous Transplantation .....	174
V.	Hematopoietic Stem Cell Sources .....	175
VI.	Cellular Therapies .....	176
VII.	Marrow Issues .....	176
VIII.	Apheresis Issues .....	176
IX.	Conditioning Regimen Issues .....	177
X.	Pharmaceutical Aspects .....	177
XI.	Acute and Chronic GVHD .....	178
XII.	Supportive Care Issues .....	178
XIII.	Prophylaxis .....	181
XIV.	Late Effects .....	181
XV.	References/Suggested Readings .....	185
	Appendix 12-1. Drug and Radiation Doses for Pediatric HSCT .....	187
<b>13.</b>	<b>Stem Cell Grafts .....</b>	<b>191</b>
	<i>Martin Körbling, MD, and Axel R. Zander, MD</i>	
I.	Introduction .....	191
II.	Biology of Cell Populations Contained in Hematopoietic Tissue-Derived Stem Cell Grafts .....	192

III.	Quantification of Graft-Containing Cells . . . . .	194
IV.	Engraftment Potential. . . . .	195
V.	Choice of Stem Cell Source in Adult Transplantation . . . . .	197
VI.	References/Suggested Readings . . . . .	198
<b>14.</b>	<b>Stem Cell Collection Techniques. . . . .</b>	<b>201</b>
	<i>Ivana N.M. Micallef, MD, FRCP(C), and Dennis A. Gastineau, MD</i>	
I.	Marrow Harvesting. . . . .	201
II.	Peripheral Blood Stem Cell Mobilization . . . . .	202
III.	Autologous Transplantation. . . . .	204
IV.	Allogeneic Transplantation . . . . .	209
V.	References/Suggested Readings . . . . .	210
<b>15.</b>	<b>Cord Blood Graft Collection and Processing . . . . .</b>	<b>213</b>
	<i>Sue Armitage, BSc, and Elizabeth J. Shpall, MD</i>	
I.	Overview. . . . .	213
II.	Types of Cord Blood Banking . . . . .	214
III.	Advantages of Cord Blood as a Source of Hematopoietic Stem Cells. . . . .	214
IV.	Disadvantages of Cord Blood as a Source of Hematopoietic Stem Cells. . . . .	215
V.	Cord Blood Banking Operations . . . . .	215
VI.	Registration of Units. . . . .	220
VII.	Clinical Results of Cord Blood Transplantation . . . . .	220
VIII.	References/Suggested Readings . . . . .	223
<b>16.</b>	<b>Laboratory Processing of Hematopoietic Progenitor Cells. . . . .</b>	<b>225</b>
	<i>Dennis A. Gastineau, MD, and Douglas J. Padley, MT(ASCP)</i>	
I.	Introduction . . . . .	225
II.	Manufacturing in the Cell Processing Laboratory . . . . .	225
III.	Plasma or Red Cell Incompatibility . . . . .	231
IV.	Donor Lymphocyte Infusion . . . . .	234
V.	HPC Product Testing . . . . .	235
VI.	Regulatory and Accreditation Issues and Process Control . . . . .	235
VII.	Other Products and Product Manufacturing. . . . .	236
VIII.	Administration of HPC Products . . . . .	237
IX.	References/Suggested Readings . . . . .	237
<b>17.</b>	<b>Hematopoietic Progenitor Cell Administration . . . . .</b>	<b>239</b>
	<i>Christopher A. Tormey, MD, and Edward L. Snyder, MD</i>	
I.	Introduction . . . . .	239
II.	Overview of HPC Components . . . . .	239
III.	Basics of HPC Administration . . . . .	240
IV.	ABO and Rh Incompatibility . . . . .	243

V.	Acute Adverse Events Associated with HPC Administration: Complications and Management . . . . .	.244
VI.	References/Suggested Readings . . . . .	.252
<b>18.</b>	<b>Engraftment . . . . .</b>	<b>255</b>
	<i>Paul V. O'Donnell, MD, PhD, FACP</i>	
I.	Introduction . . . . .	.255
II.	Factors Affecting Engraftment . . . . .	.256
III.	Chimerism . . . . .	.262
IV.	Erythroid Engraftment . . . . .	.264
V.	Engraftment Following Allogeneic HSCT from Alternative Donors . . . . .	.266
VI.	Engraftment Syndrome . . . . .	.269
VII.	References/Suggested Readings . . . . .	.271
<b>19.</b>	<b>Immune Reconstitution . . . . .</b>	<b>273</b>
	<i>Anthony D. Sung, MD; Yubin Kang, MD; and Nelson J. Chao, MD, MBA</i>	
I.	Overview of the Human Immune System . . . . .	.273
II.	Assays for Monitoring Immune Reconstitution . . . . .	.275
III.	Immune Reconstitution . . . . .	.276
IV.	Immunomodulation and Immunoenhancement . . . . .	.285
V.	Conclusion . . . . .	.286
VI.	References/Suggested Readings . . . . .	.288
<b>20.</b>	<b>Transfusion Support for Hematopoietic Stem Cell Transplantation . . . . .</b>	<b>291</b>
	<i>Erin K.G. Meyer, DO, MPH, and Zbigniew M. Szczepiorkowski, MD, PhD, FCAP</i>	
I.	Blood Component Collection and Testing . . . . .	.291
II.	Blood Components—Types and Indications . . . . .	.294
III.	Blood Components—Modifications . . . . .	.301
IV.	Adverse Events Related to Transfusion of Blood Components . . . . .	.303
V.	Transfusion Support for RBC-Incompatible Transplants . . . . .	.303
VI.	Transfusion Support for the Pediatric HSCT Patient . . . . .	.307
VII.	Therapeutic Apheresis . . . . .	.308
VIII.	References/Suggested Readings . . . . .	.313
<b>21.</b>	<b>Hematopoietic Growth Factor Support After Hematopoietic Stem Cell Transplantation . . . . .</b>	<b>315</b>
	<i>Hong Yen Ng, Bsc (Pharm) (Hons), BCOP, and Yan Jun Lim, Bsc (Pharm) (Hons), M Clin Pharm, BCOP</i>	
I.	Red Cell Growth Factors . . . . .	.315
II.	White Cell Growth Factors . . . . .	.324

III.	Megakaryocytic Growth Factors . . . . .	332
IV.	References/Suggested Readings . . . . .	334
<b>22.</b>	<b>Medical Nutrition Therapy in Hematopoietic Stem Cell Transplantation. . . . .</b>	<b>337</b>
	<i>Alison Winter-Lai, MS, RD, CSO, CDN, and Courtney McGowan, MS, RD, CSO, CNSC, CDN</i>	
I.	Nutrition Assessment Before Hematopoietic Stem Cell Transplantation . . . . .	337
II.	HSCT and Energy/Protein Needs in Adults . . . . .	340
III.	HSCT and Energy/Protein Needs in Pediatrics . . . . .	341
IV.	Maintenance Fluid Needs . . . . .	341
V.	Vitamins/Minerals . . . . .	342
VI.	Eating Problems During and After HSCT . . . . .	344
VII.	Dietary Guidelines for Immunosuppressed Patients . . . . .	344
VIII.	Nutrition Support . . . . .	347
IX.	Long-term Nutrition Considerations Following HSCT . . . . .	352
X.	Summary . . . . .	352
XI.	References/Suggested Readings . . . . .	353
<b>23.</b>	<b>Fluids and Electrolyte Management. . . . .</b>	<b>355</b>
	<i>Elizabeth C. DiMaggio, PharmD, BCOP</i>	
I.	Fluctuations During Peripheral Blood Stem Cell (PBSC) Apheresis . . . . .	363
II.	Influence of Drug Therapy Prior to HSCT . . . . .	364
III.	Electrolyte Abnormalities Following HSCT . . . . .	365
IV.	Fluid and Electrolyte Fluctuations from Supportive Therapy Following HSCT. . . . .	366
V.	Electrolyte Disturbances at Engraftment . . . . .	366
VI.	References/Suggested Readings . . . . .	367
<b>24.</b>	<b>Bacterial Infections . . . . .</b>	<b>369</b>
	<i>John R. Wingard, MD</i>	
I.	Introduction . . . . .	369
II.	Risk Factors for Bacterial Infection . . . . .	369
III.	Neutropenic Fever . . . . .	369
IV.	Bacterial Infectious Syndromes . . . . .	374
V.	Prophylaxis . . . . .	377
VI.	References/Suggested Readings . . . . .	377
<b>25.</b>	<b>Viral Infections After Engraftment. . . . .</b>	<b>379</b>
	<i>Helen Leather, BPharm, and Michael Boeckh, MD</i>	
I.	Herpes Viruses . . . . .	379
II.	Respiratory Viruses . . . . .	390

III.	Adenoviruses .....	396
IV.	Polyomaviruses .....	397
V.	References/Suggested Readings .....	399
<b>26.</b>	<b>Fungal Infections .....</b>	<b>401</b>
	<i>Shmuel Shoham, MD, and Kieren A. Marr, MD</i>	
I.	Epidemiology and Pathogenesis .....	401
II.	Prophylaxis .....	403
III.	Specific Infections .....	404
IV.	Summary .....	416
V.	References/Suggested Readings .....	416
<b>27.</b>	<b>Infectious Hepatitis in Hematopoietic Stem Cell Transplantation .....</b>	<b>419</b>
	<i>Richard A. Zuckerman, MD, MPH</i>	
I.	Introduction .....	419
II.	Pretransplant Evaluations .....	419
III.	Hepatitis A Virus .....	420
IV.	Hepatitis B Virus .....	421
V.	Hepatitis C Virus .....	425
VI.	Posttransplant Concerns .....	427
VII.	Peritransplant Immunization .....	434
VIII.	References/Suggested Readings .....	434
<b>28.</b>	<b>Posttransplant Vaccination Strategies .....</b>	<b>437</b>
	<i>Ernesto Ayala, MD, and Claudio Anasetti, MD</i>	
I.	Introduction .....	437
II.	General Concepts .....	437
III.	Vaccines Against Bacteria .....	438
IV.	Vaccines Against Viruses .....	442
V.	Serologic Testing .....	445
VI.	Donor Vaccination .....	445
VII.	Immunization of Family Members and Health-Care Workers .....	446
VIII.	References/Suggested Readings .....	446
<b>29.</b>	<b>Liver Disease After Hematopoietic Stem Cell Transplantation .....</b>	<b>449</b>
	<i>Jan S. Moreb, MD</i>	
I.	Introduction .....	449
II.	Liver Problems During Pretransplant Evaluation .....	450
III.	Drug-Induced Hepatobiliary Abnormalities Following HSCT .....	454
IV.	Nondrug-Related Liver Problems in the First 100 Days .....	458

V.	Liver Abnormalities Beyond Day 100 .....	461
VI.	References/Suggested Readings .....	464
<b>30.</b>	<b>Oral Complications in Hematopoietic Stem Cell Transplantation.....</b>	<b>465</b>
	<i>Nathaniel S. Treister, DMD, DMSC, and Stephen T. Sonis, DMD, DMSC</i>	
I.	Introduction .....	465
II.	Pre-HSCT Dental Evaluation .....	465
III.	Approach to Diagnosis in the HSCT Recipient .....	468
IV.	Oral Mucositis .....	469
V.	Oral Infections .....	472
VI.	Noninfectious Causes of Orofacial Pain .....	475
VII.	Graft-vs-Host Disease .....	476
VIII.	Second Malignancy .....	480
IX.	References/Suggested Readings .....	480
<b>31.</b>	<b>Gastrointestinal Complications of Hematopoietic Stem Cell Transplantation.....</b>	<b>481</b>
	<i>Judith Lees, BPharm, and Dorothy M. Keefe, MD</i>	
I.	Introduction .....	481
II.	Nausea and Vomiting .....	482
II.	Delayed Nausea or Vomiting Prevention .....	486
III.	Esophageal/Gastric Mucositis .....	486
IV.	Small Intestinal/Colonic Mucositis and Diarrhea.....	486
V.	Constipation .....	490
VI.	References/Suggested Readings .....	490
<b>32.</b>	<b>Lung Injury Following Hematopoietic Stem Cell Transplantation.....</b>	<b>493</b>
	<i>Kenneth R. Cooke, MD, and Gregory A. Yanik, MD</i>	
I.	Introduction .....	493
II.	Infectious Interstitial Pneumonias.....	493
III.	Idiopathic Pneumonia Syndrome .....	496
IV.	Chronic Pulmonary Dysfunction After HSCT .....	505
V.	Conclusion.....	511
VI.	References/Suggested Readings .....	512
<b>33.</b>	<b>Management of Pain in the Hematopoietic Stem Cell Transplantation Patient.....</b>	<b>513</b>
	<i>Laura E. Wiggins, PharmD, BCOP</i>	
I.	Overview .....	513
II.	Pathophysiology of Pain .....	513
III.	Types of Pain in the HSCT Patient .....	514
IV.	Diagnosis of Pain .....	517



IV.	Management of Pain .....	517
V.	Summary .....	526
VI.	References/Suggested Readings .....	526
<b>34.</b>	<b>Hemorrhagic Cystitis .....</b>	<b>529</b>
	<i>Zuzana Potáčová, MD, PhD; Tina Dalianis, MD, PhD;</i> <i>Katarina Le Blanc, MD, PhD; and Olle Ringdén, MD, PhD</i>	
I.	Overview .....	529
II.	Pathogenesis and Role of Infection .....	532
III.	Management .....	534
IV.	References/Suggested Readings .....	537
<b>35.</b>	<b>Management of Coagulopathies/Transplant-Associated Microangiopathy .....</b>	<b>539</b>
	<i>Yan Yun Wu, MD, PhD, and Peter W. Marks, MD, PhD</i>	
I.	Hemorrhagic Complications .....	539
II.	Thrombotic Complications .....	544
III.	References/Suggested Readings .....	548
<b>36.</b>	<b>Anticoagulation, Thrombosis, and Bleeding in the Hematopoietic Stem Cell Transplantation Patient .....</b>	<b>551</b>
	<i>Marc S. Zumberg, MD, and Molly Mandernach, MD, MPH</i>	
I.	Introduction .....	551
II.	Bleeding Complications After HSCT .....	552
III.	Thrombotic Complications After HSCT .....	554
IV.	Balancing the Risks of Bleeding vs the Benefits of Anticoagulation .....	556
V.	Anticoagulant Choice During HSCT .....	561
VI.	References/Suggested Readings .....	565
<b>37.</b>	<b>Hyperlipidemia After Allogeneic Hematopoietic Stem Cell Transplantation .....</b>	<b>567</b>
	<i>Bradley W. Blaser, MD, PhD; Vincent T. Ho, MD; and Robert J. Soiffer, MD</i>	
I.	Management of Hyperlipidemia Before Engraftment .....	567
II.	Management of Hyperlipidemia After Engraftment .....	568
III.	References/Suggested Readings .....	574
<b>38.</b>	<b>Neurologic Complications in Hematopoietic Stem Cell Transplantation .....</b>	<b>577</b>
	<i>Maxim Norkin, MD, PhD</i>	
I.	Introduction .....	577
II.	Neurologic Complications During the Pretransplant Period .....	577

III.	Neurologic Complications During Preengraftment . . . . .	579
IV.	Neurologic Complications After Reconstitution of Marrow Function . . . . .	593
V.	References/Suggested Reading . . . . .	596
<b>39.</b>	<b>Acute GVHD . . . . .</b>	<b>597</b>
	<i>Corey Cutler, MD, MPH, FRCP(C)</i>	
I.	Acute GVHD Pathobiology and Risk Factors . . . . .	597
II.	GVHD Prophylaxis . . . . .	599
III.	Diagnosis, Epidemiology, and Clinical Manifestations of Acute GVHD . . . . .	602
IV.	Treatment and Outcome of Acute GVHD . . . . .	606
V.	Survival After Acute GVHD . . . . .	609
VI.	References/Suggested Readings . . . . .	609
<b>40.</b>	<b>Chronic GVHD . . . . .</b>	<b>611</b>
	<i>Iskra Pusic, MD; Georgia B. Vogelsang, MD; and Steven Z. Pavletic, MD</i>	
I.	Pathophysiology of Chronic GVHD . . . . .	612
II.	Risk Factors . . . . .	612
III.	Diagnosis . . . . .	612
IV.	Classification . . . . .	613
V.	Staging . . . . .	617
VI.	Clinical Manifestations . . . . .	618
VII.	GVT Effect . . . . .	622
VIII.	Prevention . . . . .	622
IX.	Treatment . . . . .	622
X.	Measuring the Response to Therapy . . . . .	628
XI.	Monitoring Patients with Chronic GVHD . . . . .	628
XII.	Prognosis of Chronic GVHD . . . . .	628
XIII.	References/Suggested Readings . . . . .	630
<b>41.</b>	<b>Photopheresis . . . . .</b>	<b>631</b>
	<i>Joseph G. Sokhn, MD; Jaehyuk Choi, MD, PhD; and Francine M. Foss, MD</i>	
I.	Introduction . . . . .	631
II.	Collection Techniques . . . . .	631
III.	UVA Irradiation . . . . .	634
IV.	Mechanisms of ECP . . . . .	636
V.	Therapeutic Applications of Photopheresis . . . . .	638
VI.	Clinical Efficacy of ECP for Treatment of GVHD . . . . .	639
VII.	Summary . . . . .	643
VIII.	References/Suggested Readings . . . . .	643

<b>42. Late Complications: Screening and Management</b> . . . . .	<b>647</b>
<i>Navneet S. Majhail, MD, MS, and J. Douglas Rizzo, MD, MS</i>	
I. Overview . . . . .	647
II. Guidelines for Screening/Prevention of Late Complications . . . . .	647
III. Neuropsychiatric Complications . . . . .	648
IV. Ocular Complications . . . . .	648
V. Oral Complications . . . . .	656
VI. Respiratory Complications . . . . .	656
VII. Cardiac and Vascular Complications . . . . .	657
VIII. Liver Complications . . . . .	657
IX. Renal and Genitourinary Complications . . . . .	658
X. Complications of Muscle and Connective Tissue . . . . .	658
XI. Skeletal Complications . . . . .	659
XII. Nervous System Complications . . . . .	659
XIII. Endocrine Complications . . . . .	660
XIV. Mucocutaneous Complications . . . . .	660
XV. Fertility . . . . .	661
XVI. General Preventive Health . . . . .	661
XVII. References/Suggested Readings . . . . .	661
<b>43. Neuropsychiatric Complications of Hematopoietic Stem Cell Transplantation</b> . . . . .	<b>663</b>
<i>Mitchell R. Levy, MD, and Jesse R. Fann, MD, MPH</i>	
I. General Principles of Assessment and Management . . . . .	663
II. Level of Distress . . . . .	668
III. Severe Neuropsychiatric Complications . . . . .	678
IV. Cancer-Related Fatigue . . . . .	679
V. Somatization . . . . .	680
VI. Survivorship . . . . .	681
VII. References/Suggested Readings . . . . .	682
<b>44. Psychosocial Sequelae of Hematopoietic Stem Cell Transplantation in Survivors and Caregivers</b> . . . . .	<b>685</b>
<i>Michelle M. Bishop, PhD</i>	
I. Introduction . . . . .	685
II. Major Psychosocial Sequelae After HSCT . . . . .	686
III. Family Caregivers . . . . .	701
IV. References/Suggested Readings . . . . .	703
<b>45. Second Cancers</b> . . . . .	<b>705</b>
<i>Smita Bhatia, MD, MPH</i>	
I. Overview . . . . .	705
II. Therapy-Related Myelodysplasia and Acute Myeloid Leukemia After Autologous HSCT . . . . .	706

III.	Donor-Derived Hematologic Malignancies After HSCT . . . . .	711
IV.	Lymphomas . . . . .	711
V.	Solid Tumors . . . . .	713
VI.	Conclusions . . . . .	715
VII.	References/Suggested Readings . . . . .	717
<b>46.</b>	<b>Relapse After Hematopoietic Stem Cell Transplantation . . . . .</b>	<b>719</b>
	<i>Michael R. Bishop, MD</i>	
I.	Introduction . . . . .	719
II.	Biology . . . . .	720
III.	Relapse Risk . . . . .	720
IV.	Monitoring . . . . .	721
V.	Prevention of Relapse . . . . .	722
VI.	Treatment of Relapse . . . . .	722
VII.	Summary . . . . .	727
VIII.	References/Suggested Readings . . . . .	729
<b>47.</b>	<b>Donor Lymphocyte Infusion and Graft-vs-Leukemia</b>	
	<b>Effects of Allogeneic Transplantation . . . . .</b>	<b>733</b>
	<i>Hans-Jochem Kolb, MD, and Raymund Buhmann, MD</i>	
I.	Separation of GVL Effects and Graft-vs-Host Disease . . . . .	736
II.	CML . . . . .	738
III.	DLI in AML and MDS . . . . .	741
IV.	DLI in ALL . . . . .	744
V.	DLI in Chronic Lymphocytic Leukemia and Lymphoma . . . . .	744
VI.	DLI in Multiple Myeloma . . . . .	745
VII.	DLI in Solid Tumors . . . . .	745
VIII.	Immunotherapy in Patients with HLA-Haploidentical Donors . . . . .	746
IX.	Treatment of Viral Infections with Donor Lymphocytes . . . . .	746
X.	Do Donor Lymphocytes Eliminate Leukemia Stem Cells? . . . . .	747
XI.	Failure of Durable Control—Immune Escape Mechanisms . . . . .	747
XII.	Future of DLI . . . . .	749
XIII.	Acknowledgments . . . . .	749
XIV.	References/Suggested Readings . . . . .	749
<b>48.</b>	<b>Gynecologic Management of Fertility . . . . .</b>	<b>751</b>
	<i>Sanaz Ghazal, MD; Jason G. Bromer, MD; and</i>	
	<i>Pasquale Patrizio, MD, MBE</i>	
I.	Introduction . . . . .	751
II.	The Effect of Gonadotoxic Agents on Fertility . . . . .	752
III.	Established Strategies for Fertility Preservation . . . . .	753
IV.	Experimental Strategies for Fertility Preservation . . . . .	756
V.	Strategies for Ovarian Protection . . . . .	759
VI.	Ethical Considerations in Fertility Preservation . . . . .	760

VII.	Summary and Conclusions	760
VIII.	References/Suggested Readings	763
<b>49.</b>	<b>Pathogenesis, Diagnosis, and Management of Iron Overload in Hematopoietic Stem Cell Transplantation.</b>	<b>765</b>
	<i>Maxim Norkin, MD, PhD, and Ashley Richards, PharmD, BCOP</i>	
I.	Introduction	765
II.	Basic Principles of Iron Homeostasis and Pathophysiology of IO in HSCT Recipients	765
III.	Assessment and Monitoring of IO and Body Iron Burden.	766
IV.	Prevalence of IO in HSCT Recipients	770
V.	Impact of IO on Clinical Outcomes in HSCT Recipients	772
VI.	Iron Reduction Therapy in HSCT Recipients	774
VII.	Screening for IO After HSCT	779
VIII.	Monitoring the Response to IRT	779
IX.	Summary and Future Developments.	780
X.	References/Suggested Readings.	780
<b>50.</b>	<b>Dosing Considerations in Overweight and Obese Patients Receiving High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation.</b>	<b>783</b>
	<i>Dennis L. Cooper, MD</i>	
I.	Overview	783
II.	Dosing for Overweight Patients	784
III.	References/Suggested Readings	787
<b>51.</b>	<b>Common Procedures in Hematopoietic Stem Cell Transplantation</b>	<b>789</b>
	<i>Bimalangshu R. Dey, MD, PhD, and Thomas R. Spitzer, MD</i>	
I.	Introduction	789
II.	Marrow Aspiration and Biopsy	789
III.	Skin Biopsy	791
IV.	Lumbar Puncture	792
V.	Marrow Harvest	795
VI.	Apheresis	797
VII.	References/Suggested Readings	802
<b>52.</b>	<b>Data Collection and Management for Hematopoietic Stem Cell Transplantation Centers</b>	<b>805</b>
	<i>Wael Saber, MD, MS, and Mary M. Horowitz, MD, MS</i>	
I.	Introduction—Why Collect Data?	805
II.	Data Collection at the Transplant Center—Ensuring Quality and Addressing Local Research Needs.	806

III.	Outcomes Registries—Contributing to the National and International Research Enterprise . . . . .	807
IV.	Addressing Federal Requirements—the US SCTOD . . . . .	813
V.	Summary . . . . .	817
VI.	References/Suggested Readings . . . . .	817
<b>53.</b>	<b>Accreditation Standards and Quality Programs in Hematopoietic Stem Cell Transplantation. . . . .</b>	<b>819</b>
	<i>Michele W. Sugrue, MS, MT(ASCP)SBB;</i>	
	<i>Zbigniew M. Szczepiorkowski, MD, PhD; and</i>	
	<i>Dennis A. Gastineau, MD</i>	
I.	Quality Management Systems in Clinical Practice . . . . .	819
II.	Change Control . . . . .	824
III.	The Quality Committee . . . . .	824
IV.	Interruption of Services . . . . .	824
V.	Accreditation and Standards . . . . .	825
VI.	United States Food and Drug Administration (FDA) Regulations and Oversight . . . . .	832
VII.	Conclusion . . . . .	835
VIII.	References/Suggested Readings . . . . .	836
<b>54.</b>	<b>Financial Aspects of Hematopoietic Stem Cell Transplantation. . . . .</b>	<b>837</b>
	<i>Richard T. Maziarz, MD; Jeffrey W. Chell, MD; and</i>	
	<i>Richard E. Champlin, MD</i>	
I.	Introduction . . . . .	837
II.	Increase in Utilization and Impact of HSCT on National Health-Care Costs . . . . .	838
III.	Complexity of Care Increases Costs . . . . .	840
IV.	Payer Source . . . . .	841
V.	Contracts and Reimbursement Strategies . . . . .	843
VI.	Resource Utilization . . . . .	844
VII.	Research . . . . .	846
VIII.	Quality . . . . .	848
IX.	Future Considerations . . . . .	848
X.	Summary . . . . .	849
XI.	References/Suggested Readings . . . . .	851
<b>Appendices</b>		
	Appendix 1. Antibacterial Adult Dosage Guidelines for Patients with Normal Renal Function and Renal Insufficiency (As of January 2013) . . . . .	853
	Appendix 2. Antifungal Adult Dosage Guidelines for Patients with Normal Renal Function and Renal Insufficiency (As of January 2013) . . . . .	873

---

Appendix 3. Antiviral Adult Dosage Guidelines for Renal Insufficiency (as of January 2013) . . . . .	879
Appendix 4. Drug Interactions with Antifungal Agents Cytochrome P450 Isoenzymes Involved in Drug Metabolism . . . . .	885
Appendix 5. Clinically Relevant Pharmacokinetic Drug Interactions with Ketoconazole . . . . .	889
Appendix 6. Clinically Relevant Pharmacokinetic Drug Interactions with Fluconazole . . . . .	893
Appendix 7. Clinically Relevant Pharmacokinetic Drug Interactions with Itraconazole . . . . .	895
Appendix 8. Clinically Relevant Pharmacokinetic Drug Interactions with Voriconazole: Effect of Voriconazole on the Pharmacokinetics of Other Drugs . . . . .	899
Appendix 9. Clinically Relevant Pharmacokinetic Drug Interactions with Voriconazole: Effect of Other Drugs on the Pharmacokinetics of Voriconazole . . . . .	905
Appendix 10. Drug Interactions with Posaconazole . . . . .	907
Appendix 11. Clinically Relevant Pharmacokinetic Drug Interactions with Tacrolimus . . . . .	911
Appendix 12. Clinically Relevant Pharmacokinetic Drug Interactions with Cyclosporine . . . . .	915
Appendix 13. Clinically Relevant Pharmacokinetic Drug Interactions with Sirolimus . . . . .	919
Appendix 14. Cyclosporine Dosing and Monitoring Guidelines . . . . .	923
Appendix 15. Tacrolimus Dosing and Monitoring Guidelines . . . . .	925
Index . . . . .	929

Bonus References Are Located on USB Flash Card

